Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
Decline in respiratory function in patients with DMD starts during early teenage years and leads to early morbidity and mortality. Published evidence of efficacy for idebenone on respiratory function outcomes is currently limited to 12 months of follow-up time. Here we report data collected as retro...
Hlavní autoři: | Servais, L, Straathof, CSM, Schara, U, Klein, A, Leinonen, M, Hasham, S, Meier, T, De Waele, L, Gordish-Dressman, H, McDonald, CM, Mayer, OH, Voit, T, Mercuri, E, Buyse, GM |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Elsevier
2019
|
Podobné jednotky
-
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
Autor: Theodora Markati, a další
Vydáno: (2021-11-01) -
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
Autor: Marshall W. Hogarth, a další
Vydáno: (2017-01-01) -
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
Autor: Fatima Amor, a další
Vydáno: (2021-06-01) -
Duchenne Muscular Dystrophy
Autor: J Gordon Millichap
Vydáno: (1989-05-01) -
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Autor: Frank, DE, a další
Vydáno: (2020)